Assessing the Efficacy and Safety of Selective Metabolically Adaptive Radiation Dose Escalation in Locally Advanced Non-Small Cell Lung Cancer Receiving Definitive Chemoradiotherapy
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients who are at least 18 years old and are able to consent
Patients who will undergo Chemo-RT as primarily modality of treatment
Patients with a primary tumor or node measuring at least 10mm on CT scan
Patients with a PET avid tumor having Standardized Uptake Values (SUV) \> 4
Patients with Eastern Cooperative Oncology Group (ECOG) status 0-2 within 4 weeks of randomization
You may not be if
Trimodality patients who have surgery as part of curative treatment
Previous radiotherapy to intended treatment volumes
Active invasive malignancy other than lung cancer
Active pregnancy
Poor respiratory function (Forced Expiratory Volume \< 1.0 or Diffusing Capacity \< 50% age-adjusted normal)
ECOG status \> 2
Pre-treatment complete blood count/differential showing inadequate bone marrow reserve (absolute neutrophil count \< 1800 cells/mm3 or platelets \< 100 000 cells/mm3 or hemoglobin \< 90g/L), measured within 4 weeks of registration
AST, ALT or total bilirubin \> 2.5 times the upper limit of normal, measured within 4 weeks of registration
Unintentional weight loss \>10% over 3 months within 4 weeks of registration
Severe active co-morbidity defined by:
Significant history of uncontrolled cardiac disease; i.e. uncontrolled hypertension, unstable angina, myocardial infarction within the last 6 months, uncontrolled congestive heart failure, cardiomyopathy with decreased ejection fraction
Transmural myocardial infection requiring intravenous antibiotics at the time of registration
Chronic Obstructive Pulmonary Disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy within 30 days before randomization
Acquired immune deficiency syndrome (AIDS) based on the current Centre for Disease Control definition; note, however, that HIV testing is not required for entry into this protocol
Clareo Health | Assessing the Efficacy and Safety of Selective Metabolically Adaptive Radiation Dose Escalation in Locally Advanced Non-Small Cell Lung Cancer Receiving Definitive Chemoradiotherapy
